Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years

D. Horáková, A. Boster, A. Bertolotto, MS. Freedman, I. Firmino, SJ. Cavalier, AK. Jacobs, K. Thangavelu, N. Daizadeh, EM. Poole, DP. Baker, DH. Margolin, T. Ziemssen, CARE-MS I, CARE-MS II, and CAMMS03409 Investigators

. 2020 ; 6 (4) : 2055217320972137. [pub] 20201218

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21010216

Background: Few data exist concerning conversion to secondary progressive MS in patients treated with disease-modifying therapies. Objective: Determine the proportion of alemtuzumab-treated patients converting from relapsing-remitting to secondary progressive MS during the CARE-MS core and extension studies. Methods: Patients (N = 811) were analyzed post hoc for secondary progressive MS conversion. Optimal conversion definition: Expanded Disability Status Scale (EDSS) score ≥4, pyramidal functional system score ≥2, and confirmed progression over ≥3 months including confirmation within the functional system leading to progression, independent of relapse. Results: Over 6.2 years median follow-up, 20 alemtuzumab-treated patients converted (Kaplan-Meier estimate, 2.7%; 95% confidence interval, 1.8%-4.2%). Sensitivity analysis accounting for dropouts showed similar results (3%), as did analyses using alternative definitions with different EDSS thresholds and/or confirmation periods, and analysis of core study subcutaneous interferon beta-1a-treated patients who received alemtuzumab in the extension. Patients converting to secondary progressive MS were older, and had higher EDSS scores and greater brain lesion volumes at baseline, but did not need additional alemtuzumab or other therapies. Conclusions: The 6-year conversion rate to secondary progressive MS was low for alemtuzumab-treated patients, supporting further study of the role alemtuzumab may play in reducing risk of secondary progression.ClinicalTrials.gov identifiers: NCT00530348, NCT00548405, NCT00930553.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21010216
003      
CZ-PrNML
005      
20210610101119.0
007      
ta
008      
210413s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/2055217320972137 $2 doi
035    __
$a (PubMed)33414927
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Horáková, Dana $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
245    10
$a Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years / $c D. Horáková, A. Boster, A. Bertolotto, MS. Freedman, I. Firmino, SJ. Cavalier, AK. Jacobs, K. Thangavelu, N. Daizadeh, EM. Poole, DP. Baker, DH. Margolin, T. Ziemssen, CARE-MS I, CARE-MS II, and CAMMS03409 Investigators
520    9_
$a Background: Few data exist concerning conversion to secondary progressive MS in patients treated with disease-modifying therapies. Objective: Determine the proportion of alemtuzumab-treated patients converting from relapsing-remitting to secondary progressive MS during the CARE-MS core and extension studies. Methods: Patients (N = 811) were analyzed post hoc for secondary progressive MS conversion. Optimal conversion definition: Expanded Disability Status Scale (EDSS) score ≥4, pyramidal functional system score ≥2, and confirmed progression over ≥3 months including confirmation within the functional system leading to progression, independent of relapse. Results: Over 6.2 years median follow-up, 20 alemtuzumab-treated patients converted (Kaplan-Meier estimate, 2.7%; 95% confidence interval, 1.8%-4.2%). Sensitivity analysis accounting for dropouts showed similar results (3%), as did analyses using alternative definitions with different EDSS thresholds and/or confirmation periods, and analysis of core study subcutaneous interferon beta-1a-treated patients who received alemtuzumab in the extension. Patients converting to secondary progressive MS were older, and had higher EDSS scores and greater brain lesion volumes at baseline, but did not need additional alemtuzumab or other therapies. Conclusions: The 6-year conversion rate to secondary progressive MS was low for alemtuzumab-treated patients, supporting further study of the role alemtuzumab may play in reducing risk of secondary progression.ClinicalTrials.gov identifiers: NCT00530348, NCT00548405, NCT00930553.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Boster, Aaron $u The Boster Center for Multiple Sclerosis, Columbus, USA
700    1_
$a Bertolotto, Antonio $u AOU San Luigi, Orbassano, Torino, Italy
700    1_
$a Freedman, Mark S $u University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, Canada
700    1_
$a Firmino, Isabel
700    1_
$a Cavalier, Steven J
700    1_
$a Jacobs, Alan K
700    1_
$a Thangavelu, Karthinathan
700    1_
$a Daizadeh, Nadia
700    1_
$a Poole, Elizabeth M
700    1_
$a Baker, Darren P
700    1_
$a Margolin, David H $u Sanofi, Cambridge, USA
700    1_
$a Ziemssen, Tjalf $u Center of Clinical Neuroscience, Carl Gustav Carus University Hospital, Dresden, Germany Employees of Sanofi during study conduct and analysis
710    2_
$a CARE-MS I, CARE-MS II, and CAMMS03409 Investigators
773    0_
$w MED00194908 $t Multiple sclerosis journal - experimental, translational and clinical $x 2055-2173 $g Roč. 6, č. 4 (2020), s. 2055217320972137
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33414927 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210413 $b ABA008
991    __
$a 20210610101118 $b ABA008
999    __
$a ind $b bmc $g 1649729 $s 1130592
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 6 $c 4 $d 2055217320972137 $e 20201218 $i 2055-2173 $m Multiple sclerosis journal - experimental, translational and clinical $n Mult Scler J Exp Transl Clin $x MED00194908
LZP    __
$a Pubmed-20210413

Find record

Citation metrics

Archiving options